aTYR PHARMA (ATYR) Minority Interest (2019 - 2026)
aTYR PHARMA's (ATYR) quarterly Minority Interest came in at -$194000.0 in Q2 2026, down 2.65% on a YoY basis from -$199271.7 in Q2 2025, and down 0.52% quarter-over-quarter from -$193000.0 in Q1 2026.
Powered by 
Analysis
aTYR PHARMA (ATYR) Minority Interest (2019 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has reported Minority Interest for 8 consecutive years, with -$194000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Minority Interest fell 2.65% year-over-year to -$194000.0; the trailing twelve-month figure through Jun 2026 stood at -$194000.0 (down 2.65% YoY), and the FY2025 full-year result was -$192000.0, down 2.67% from the prior year.
- Minority Interest declined to -$194000.0 in Q2 2026 per ATYR's latest filing, from -$193000.0 in the prior quarter.
- Across five years, Minority Interest topped out at -$176000.0 in Q1 2022 and bottomed at -$194000.0 in Q2 2026.
- Historically, Minority Interest has averaged -$185555.6 across 5 years, with a median of -$186500.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Minority Interest fell 5.06% in 2023, then advanced 0.54% in 2024.
- Over 5 years, Minority Interest stood at -$180000.0 in 2022, then slipped by 4.44% to -$188000.0 in 2023, then increased by 0.53% to -$187000.0 in 2024, then decreased by 2.67% to -$192000.0 in 2025, then decreased by 1.04% to -$194000.0 in 2026.
- According to Business Quant data, Minority Interest over the past three periods registered -$194000.0, -$193000.0, and -$192000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -194,000.00 |
| Mar 31, 2026 | -193,000.00 |
| Dec 31, 2025 | -192,000.00 |
| Sep 30, 2025 | -191,000.00 |
| Jun 30, 2025 | -189,000.00 |
| Mar 31, 2025 | -188,000.00 |
| Dec 31, 2024 | -187,000.00 |
| Sep 30, 2024 | -186,000.00 |
| Jun 30, 2024 | -184,000.00 |
| Mar 31, 2024 | -184,000.00 |
| Dec 31, 2023 | -188,000.00 |
| Sep 30, 2023 | -187,000.00 |
| Jun 30, 2023 | -185,000.00 |
| Mar 31, 2023 | -181,000.00 |
| Dec 31, 2022 | -180,000.00 |
| Sep 30, 2022 | -178,000.00 |
| Jun 30, 2022 | -177,000.00 |
| Mar 31, 2022 | -176,000.00 |
| Dec 31, 2021 | -175,000.00 |
| Sep 30, 2021 | -173,000.00 |